11:41 AM
Dec 20, 2016
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML); breast cancer; ovarian cancer

Cell culture and mouse studies suggest a GAS6-binding AXL decoy could help treat AML and metastatic breast and ovarian cancers. The AXL decoy, Aravive-S6, consisted of a...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >